Latest Breaking News On - Alexandra weingarten - Page 1 : vimarsana.com

Kura Oncology to Report First Quarter 2024 Financial Results - Kura Oncology (NASDAQ:KURA)

SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today

Alexandra weingartenCorporate communicationsKura oncology incVice presidentInvestor relations

Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML

– Ziftomenib is the first investigational treatment to be granted Breakthrough Therapy Designation for NPM1-mutant AML – – Registration-directed trial of ziftomenib in NPM1-mutant AML on track.

Alexandra weingartenTroy wilsonKura oncology incDrug administrationGlobenewswire incExchange commissionCorporate communicationsBreakthrough therapy designationChief executive officerOrphan drug designationVice presidentInvestor relationsBreakthrough therapy

Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

– Positive preliminary combination data from KOMET-007 trial of ziftomenib in NPM1-m and KMT2A-r AML, including effective mitigation of differentiation syndrome – – First patient dosed in.

Troy wilsonAlexandra weingartenExchange commissionGlobenewswire incInvestor relations corporate communicationsKura oncology incChief executive officerLymphoma societyPediatric acute leukemiaMaster clinicalMirati therapeuticsOperations dataVice presidentInvestor relations

Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia

Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Troy wilsonAlexandra weingartenSamer zeidanCompany formKura oncology incInvestor relations corporate communicationsDrug administrationCorporate communicationsExchange commissionDivision of hematologic malignanciesHematologic malignanciesHematology early therapeutics researchYale cancer centerChief executive officerOrphan drug designationPete de spain

Kura Oncology s Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society s Pediatric Acute Leukemia (PedAL) Master Clinical Trial -December 08, 2023 at 07:30 am EST

SAN DIEGO, Dec. 08, 2023 Kura Oncology, Inc. , a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, and The Leukemia.

United statesNew zealandRyan mcdonaldGwen nicholsAlexandra weingartenMollie leoniClinical developmentKura oncology incCorporate communicationsFast companyLeukemia lymphoma societyGlobenewswire incInformation resource centerScience communicationsExchange commissionDrug administration